Core Viewpoint - MicroPort Medical announced the publication of the TARGET-FIRST clinical study results for its Firehawk® drug-eluting stent system in the New England Journal of Medicine, highlighting a significant reduction in dual antiplatelet therapy duration for low-risk acute myocardial infarction patients without increasing ischemic risk [1] Group 1 - The Firehawk® stent allows for a reduction in dual antiplatelet therapy (DAPT) duration from 12 months to 1 month for patients achieving complete revascularization [1] - The study results were presented at the European Society of Cardiology 2025 Congress in Spain, under the "Latest Breakthrough Clinical Trials (HOT LINE)" session [1] - The shortened DAPT duration not only does not increase ischemic risk but also significantly reduces bleeding complications [1]
微创医疗(00853.HK)：《新英格兰医学杂志》与欧洲心脏病学大会同步发表循证医学结果，证实植入Firehawk®╱火鹰®支架低风险心肌梗死患者实际仅需1个月双抗疗程且出血并发症减少54%